Intra-Cellular Therapies Inc. - stock earnings
ITCI Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 7, 2024 AfterMarket | -0.16 / -0.34 | - | 144.9 million / 142.9 million | - |
ITCI Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -28.6 million USD | 131.5 million USD |
| 2023Q3 | -24.3 million USD | 125.8 million USD |
| 2023Q2 | -42.8 million USD | 110.1 million USD |
| 2023Q1 | -44.1 million USD | 94.7 million USD |
| 2022Q4 | -37.3 million USD | 87.4 million USD |
| 2022Q3 | -53.5 million USD | 71.9 million USD |
| 2022Q2 | -84.0 million USD | 55.1 million USD |
| 2022Q1 | -72.1 million USD | 34.8 million USD |
| 2021Q4 | -85.7 million USD | 25.5 million USD |
| 2021Q3 | -76.9 million USD | 21.6 million USD |
| 2021Q2 | -68.7 million USD | 19.0 million USD |
| 2021Q1 | -52.7 million USD | 15.6 million USD |
| 2020Q4 | -60.7 million USD | 12.4 million USD |
| 2020Q3 | -55.2 million USD | 7.4 million USD |
| 2020Q2 | -63.7 million USD | 1.9 million USD |
| 2020Q1 | -47.4 million USD | 882516 USD |
| 2019Q4 | -40.6 million USD | 60613 USD |
| 2019Q3 | -34.9 million USD | ? USD |
| 2019Q2 | -37.4 million USD | ? USD |
| 2019Q1 | -34.8 million USD | ? USD |
| 2018Q4 | -40.7 million USD | ? USD |
| 2018Q3 | -41.5 million USD | ? USD |
| 2018Q2 | -37.4 million USD | ? USD |
| 2018Q1 | -35.5 million USD | 5055 USD |
| 2017Q4 | -30.2 million USD | 5055 USD |
| 2017Q3 | -22.9 million USD | 30754 USD |
| 2017Q2 | -17.8 million USD | 114741 USD |
| 2017Q1 | -26.9 million USD | 95287 USD |
| 2016Q4 | -27.5 million USD | 97895 USD |
| 2016Q3 | -30.3 million USD | 4362 USD |
| 2016Q2 | -30.8 million USD | 228445 USD |
| 2016Q1 | -27.8 million USD | ? USD |
| 2015Q4 | -28.8 million USD | 30659 USD |
| 2015Q3 | -32.2 million USD | 57000 USD |
| 2015Q2 | -21.5 million USD | 57390 USD |
| 2015Q1 | -22.3 million USD | 3315 USD |
| 2014Q4 | -15.2 million USD | 65862 USD |
| 2014Q3 | -6.4 million USD | 124414 USD |
| 2014Q2 | -4.5 million USD | 219238 USD |
| 2014Q1 | -4.5 million USD | 167787 USD |
| 2013Q4 | -8.0 million USD | 827531 USD |
| 2013Q3 | -4.9 million USD | 667955 USD |
| 2013Q2 | -16.9 million USD | -129.6 million USD |
| 2013Q1 | -16.9 million USD | -64.8 million USD |
| 2012Q4 | ? USD | 669000 USD |
| 2012Q3 | ? USD | 378000 USD |
| 2012Q2 | ? USD | 2.1 million USD |
| 2011Q4 | 11.1 million USD | 23.4 million USD |
ITCI Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -139.7 million USD | 462.2 million USD |
| 2022 | -256.3 million USD | 249.1 million USD |
| 2021 | -284.1 million USD | 81.7 million USD |
| 2020 | -227.0 million USD | 22.5 million USD |
| 2019 | -147.7 million USD | 60613 USD |
| 2018 | -155.1 million USD | ? USD |
| 2017 | -97.8 million USD | 245837 USD |
| 2016 | -116.4 million USD | 330702 USD |
| 2015 | -104.8 million USD | 91364 USD |
| 2014 | -30.7 million USD | 577301 USD |
| 2013 | -26.9 million USD | 2.7 million USD |
| 2012 | -16.6 million USD | 3.1 million USD |
| 2011 | 11.1 million USD | 23.4 million USD |
ITCI
Price: $67.32
52 week price:
Earnings Per Share: -1.46 USD
P/E Ratio: -44.44
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 307914
Ebitda: -22.8 millionMarket Capitalization: 7.3 billion